Experience in patients with a history of malignancy through 3 years of continuous treatment with guselkumab in the VOYAGE 1 and 2 trials - 22/08/19
A. Blauvelt, Oregon Medical Research Center, Portland, OR; K. A. Papp, K. Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada; V. Ho, Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada; K. Ghoreschi, Department of Dermatology, University Medical Center, Tübingen, Germany; B. S. Kim, Pusan National University Hospital, Busan, South Korea; Y-K. Shen, Janssen Research & Development, LLC, Spring House, PA; P. Ramachandran, Janssen Research & Development, LLC, Spring House, PA; M. Song, Janssen Research & Development, LLC, Spring House, PA; J. Uy, Janssen Scientific Affairs, LLC, Horsham, PA; J. Crowley, Bakersfield Dermatology and Skin Cancer Medical Group, Bakersfield, CA
Le texte complet de cet article est disponible en PDF. Supported 100% by Janssen Research & Development. |
Vol 81 - N° 4S1
P. AB63 - octobre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?